Advertisement
Singapore markets closed

  • Straits Times Index

    3,287.75
    -5.38 (-0.16%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • Dow

    38,460.92
    -42.77 (-0.11%)
     

  • Nasdaq

    15,712.75
    +16.11 (+0.10%)
     

  • Bitcoin USD

    63,796.01
    -2,823.06 (-4.24%)
     

  • CMC Crypto 200

    1,357.93
    -24.65 (-1.78%)
     

  • FTSE 100

    8,095.55
    +55.17 (+0.69%)
     

  • Gold

    2,340.50
    +2.10 (+0.09%)
     

  • Crude Oil

    82.99
    +0.18 (+0.22%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • Nikkei

    37,628.48
    -831.60 (-2.16%)
     

  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     

  • FTSE Bursa Malaysia

    1,569.25
    -2.23 (-0.14%)
     

  • Jakarta Composite Index

    7,155.29
    -19.24 (-0.27%)
     

  • PSE Index

    6,574.88
    +2.13 (+0.03%)
     

Company News for Apr 2, 2020

Zacks Equity Research
·1-min read

  • Shares of Chembio Diagnostics, Inc. CEMI surged 39.8% after the company launched the rapid DPP COVID-19 serological point-of-care test for the detection of IgM and IgG antibodies in the United States.

  • Shares of DPW Holdings, Inc. DPW gained 21.2% after the power system solutions developer said that its Coolisys Power Electronics Business has received a $1,283,000 purchase order from a defense contractor.

  • Shares of Trxade Group, Inc. MEDS gained 13.7% after the pharmaceutical products distributor filed FDA emergency use authorization for rapid coronavirus testing kit.

  • Shares of Inseego Corp. INSG rose 11.6% after the company said it was raising production of its 4G and 5G MiFi mobile hotspots to meet a “record increase in demand” for secure home internet access.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Chembio Diagnostics, Inc. (CEMI) : Free Stock Analysis Report
 
Inseego Corp. (INSG) : Free Stock Analysis Report
 
Trxade Group, Inc. (MEDS) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research